Nanobiotix Announced At ESMO Saturday, Phase 1 JNJ-1900 Data Showing 41.7% Response Rate, With 4 Complete Responses, 75% Disease Control Rate, 17.8-Month Median Overall Survival In Heavily Pretreated Anti-PD-1-Resistant Advanced Melanoma
Share
Why It Matters
Nanobiotix shared early test results for a new cancer medicine. The results looked promising, so watch if the company moves forward carefully.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.